Ethnicity-Based Tradipitant Dosing for Motion Sickness
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for motion sickness, primarily antihistamines and anticholinergics, are not effective for all patients and have significant side effects, and there is a need for more targeted approaches given the increasing prevalence of the disorder.
Innovation Solution
Administering tradipitant, a selective neurokinin-1 (NK-1) receptor antagonist, based on the ethnicity of the individual, with specific dosing for Hispanic and non-Hispanic individuals to prevent or treat motion sickness symptoms such as nausea, vomiting, dizziness, and disorientation before engaging in sickness-inducing activities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tradipitant is administered at a standard dose to all patients, then the treatment approach is simple and easy to implement, but the treatment effect varies significantly across different ethnic groups reducing overall efficacy
Solution Approach 1:
The patent applies local quality by differentiating the dosing regimen according to ethnic groups. Hispanic individuals receive a lower dose (e.g., 85 mg or 170 mg) compared to non-Hispanic individuals (e.g., 170 mg or 255 mg), recognizing that different populations have different sensitivities to the drug's effects. This targeted approach improves treatment reliability for each specific group while managing the complexity through clear ethnic-based categorization.
2Reliability
If ethnicity-based dosing is implemented, then treatment effectiveness is improved for different population groups, but the complexity of the treatment protocol increases
Solution Approach 1:
The patent implements parameter changes by modifying the dose parameter based on ethnic classification. The system changes the administered dose from a uniform standard to variable doses specific to Hispanic and non-Hispanic populations. This approach improves treatment effectiveness by accounting for ethnic differences in drug response, while the complexity is managed through straightforward ethnic identification and corresponding dose selection.
3Reliability
If a higher dose of tradipitant is administered, then the prevention of motion sickness symptoms is more effective, but the risk of side effects and adverse reactions increases
Solution Approach 1:
The patent applies local quality by tailoring the dose to the specific ethnic population, recognizing that Hispanic individuals may be more sensitive to tradipitant's effects. By providing a lower dose to Hispanic patients and a higher dose to non-Hispanic patients, the treatment achieves effective motion sickness prevention for each group while minimizing side effects through personalized dosing rather than using a one-size-fits-all approach.
Data Source
AI summary
Disclosed herein is an improved method of treating or preventing motion sickness or at least one symptom thereof, comprising treatment with the NK-1 receptor antagonist, tradipitant based on ethnicity of the individual to be treated.